Podcasts about gcvl

Play Episode Listen Later Apr 25, 2016 6:19

Dr. Jed Gorden, Swedish Cancer Institute, reviews the lung cancer screening process, including low-dose CT scanning, smoking cessation, follow-up testing and counseling, and describes the potential benefits.

history cancer institute patients swedish smoking screenings lung jed high risk pulmonary cessation nsclc potential benefits gorden lung cancer screening low dose nodules screening process gracecast cancergrace swedish cancer institute jed gorden gcvl gcvllung

Lung Cancer Screening - Process and Potential Benefits

Play Episode Listen Later Apr 25, 2016 6:19

Dr. Jed Gorden, Swedish Cancer Institute, reviews the lung cancer screening process, including low-dose CT scanning, smoking cessation, follow-up testing and counseling, and describes the potential benefits.

history cancer institute patients swedish smoking screenings lung jed high risk pulmonary cessation nsclc potential benefits gorden lung cancer screening low dose nodules screening process gracecast cancergrace swedish cancer institute jed gorden gcvl gcvllung

Bronchoscopy and EBUS

Play Episode Listen Later Apr 24, 2016 5:54

Dr. Jed Gorden, Swedish Cancer Institute, describes the differences between bronchoscopy and endobronchial ultrasound, highlighting the advantages of EBUS in diagnosis and staging.

cancer institute swedish conscious diagnosis lung jed staging ultrasounds anesthesia nodes airway lymph sedation gorden trachea bronchoscopy ebus bronchi gracecast cancergrace endobronchial swedish cancer institute jed gorden gcvl gcvllung

Bronchoscopy and EBUS

Play Episode Listen Later Apr 24, 2016 5:54

Dr. Jed Gorden, Swedish Cancer Institute, describes the differences between bronchoscopy and endobronchial ultrasound, highlighting the advantages of EBUS in diagnosis and staging.

cancer institute swedish conscious diagnosis lung jed staging ultrasounds anesthesia nodes airway lymph sedation gorden trachea bronchoscopy ebus bronchi gracecast cancergrace endobronchial swedish cancer institute jed gorden gcvl gcvllung

Bronchoscopy and EBUS

Play Episode Listen Later Apr 24, 2016 5:54

Dr. Jed Gorden, Swedish Cancer Institute, describes the differences between bronchoscopy and endobronchial ultrasound, highlighting the advantages of EBUS in diagnosis and staging.

cancer institute swedish conscious diagnosis lung jed staging ultrasounds anesthesia nodes airway lymph sedation gorden trachea bronchoscopy ebus bronchi gracecast cancergrace endobronchial swedish cancer institute jed gorden gcvl gcvllung

Rociletinib/Osimertinib for EGFR T790M-negative NSCLC

Play Episode Listen Later Apr 20, 2016 5:20

Dr. Jack West, Swedish Cancer Institute, reviews trial evidence for the efficacy of rociletinib and osimertinib for EGFR acquired resistance not driven by a T790M mutation.

west cancer institute resistance negative swedish lung acquired egfr nsclc jack west osimertinib gracecast t790m cancergrace swedish cancer institute necitumumab gcvl gcvllung azd9291 rebiopsy co1686 rociletinib

Rociletinib/Osimertinib for EGFR T790M-negative NSCLC

Play Episode Listen Later Apr 20, 2016 5:20

Dr. Jack West, Swedish Cancer Institute, reviews trial evidence for the efficacy of rociletinib and osimertinib for EGFR acquired resistance not driven by a T790M mutation.

west cancer institute resistance negative swedish lung acquired egfr nsclc jack west osimertinib gracecast t790m cancergrace swedish cancer institute necitumumab gcvl gcvllung azd9291 rebiopsy co1686 rociletinib

Rociletinib/Osimertinib for EGFR T790M-negative NSCLC

Play Episode Listen Later Apr 20, 2016 5:20

Dr. Jack West, Swedish Cancer Institute, reviews trial evidence for the efficacy of rociletinib and osimertinib for EGFR acquired resistance not driven by a T790M mutation.

west cancer institute resistance negative swedish lung acquired egfr nsclc jack west osimertinib gracecast t790m cancergrace swedish cancer institute necitumumab gcvl gcvllung azd9291 rebiopsy co1686 rociletinib

Are There Clinically Significant Distinctions Between PD-1 and PD-L1?

Play Episode Listen Later Apr 19, 2016 3:29

Dr. Jack West, Swedish Cancer Institute, compares the mechanism of action, efficacy and toxicity of PD-1 and PD-L1 inhibitors.

west cancer institute swedish significant pd immune lung checkpoint immunotherapy distinctions clinically inhibitors nsclc pd l1 keytruda pembrolizumab nivolumab jack west pd1 atezolizumab opdivo gracecast cancergrace swedish cancer institute gcvllung gcvl

Are There Clinically Significant Distinctions Between PD-1 and PD-L1?

Play Episode Listen Later Apr 19, 2016 3:29

Dr. Jack West, Swedish Cancer Institute, compares the mechanism of action, efficacy and toxicity of PD-1 and PD-L1 inhibitors.

west cancer institute swedish significant pd immune lung checkpoint immunotherapy distinctions clinically inhibitors nsclc pd l1 keytruda pembrolizumab nivolumab jack west pd1 atezolizumab opdivo gracecast cancergrace swedish cancer institute gcvllung gcvl

Are There Clinically Significant Distinctions Between PD-1 and PD-L1?

Play Episode Listen Later Apr 19, 2016 3:29

Dr. Jack West, Swedish Cancer Institute, compares the mechanism of action, efficacy and toxicity of PD-1 and PD-L1 inhibitors.

west cancer institute swedish significant pd immune lung checkpoint immunotherapy distinctions clinically inhibitors nsclc pd l1 keytruda pembrolizumab nivolumab jack west pd1 atezolizumab opdivo gracecast cancergrace swedish cancer institute gcvllung gcvl

Histology-Specific Recommendations - Large-Cell Neuroendocrine

Play Episode Listen Later Apr 18, 2016 2:24

Dr. Jack West, Swedish Cancer Institute, identifies the best choice for first-line chemotherapy for large-cell neuroendocrine histology.

west cancer institute stage large swedish iv recommendations platinum lung nsclc sclc histology double t neuroendocrine jack west cisplatin carboplatin gracecast cancergrace etoposide swedish cancer institute gcvl gcvllung

Histology-Specific Recommendations - Large-Cell Neuroendocrine

Play Episode Listen Later Apr 18, 2016 2:24

Dr. Jack West, Swedish Cancer Institute, identifies the best choice for first-line chemotherapy for large-cell neuroendocrine histology.

west cancer institute stage large swedish iv recommendations platinum lung nsclc sclc histology double t neuroendocrine jack west cisplatin carboplatin gracecast cancergrace etoposide swedish cancer institute gcvl gcvllung

Histology-Specific Recommendations - Large-Cell Neuroendocrine

Play Episode Listen Later Apr 18, 2016 2:24

Dr. Jack West, Swedish Cancer Institute, identifies the best choice for first-line chemotherapy for large-cell neuroendocrine histology.

west cancer institute stage large swedish iv recommendations platinum lung nsclc sclc histology double t neuroendocrine jack west cisplatin carboplatin gracecast cancergrace etoposide swedish cancer institute gcvl gcvllung

Histology-Specific Regimens - Squamous

Play Episode Listen Later Apr 17, 2016 4:02

Dr. Jack West, Swedish Cancer Institute, reviews the choices for a first-line chemotherapy regimen based on a squamous histology.

west cancer institute stage swedish iv platinum lung nab nsclc histology double t avastin jack west squamous cisplatin paclitaxel taxol docetaxel gemcitabine carboplatin gracecast cancergrace abraxane taxane taxotere swedish cancer institute alimta pemetrexed gemzar gcvl gcvllung

Histology-Specific Regimens - Squamous

Play Episode Listen Later Apr 17, 2016 4:02

Dr. Jack West, Swedish Cancer Institute, reviews the choices for a first-line chemotherapy regimen based on a squamous histology.

west cancer institute stage swedish iv platinum lung nab nsclc histology double t avastin jack west squamous cisplatin paclitaxel taxol docetaxel gemcitabine carboplatin gracecast cancergrace abraxane taxane taxotere swedish cancer institute alimta pemetrexed gemzar gcvl gcvllung

Histology-Specific Regimens - Squamous

Play Episode Listen Later Apr 17, 2016 4:02

Dr. Jack West, Swedish Cancer Institute, reviews the choices for a first-line chemotherapy regimen based on a squamous histology.

west cancer institute stage swedish iv platinum lung nab nsclc histology double t avastin jack west squamous cisplatin paclitaxel taxol docetaxel gemcitabine carboplatin gracecast cancergrace abraxane taxane taxotere swedish cancer institute alimta pemetrexed gemzar gcvl gcvllung

Histology-Specific Regimens - Adenocarcinoma

Play Episode Listen Later Apr 16, 2016 2:53

Dr. Jack West, Swedish Cancer Institute, addresses the issue of choosing a first-line chemotherapy regimen based on an adenocarcinoma histology.

west cancer institute stage swedish iv platinum lung nsclc histology double t adenocarcinoma jack west squamous cisplatin paclitaxel taxol docetaxel gemcitabine carboplatin gracecast cancergrace taxane taxotere swedish cancer institute alimta gemzar pemetrexed gcvl gcvllung

Histology-Specific Regimens - Adenocarcinoma

Play Episode Listen Later Apr 16, 2016 2:53

Dr. Jack West, Swedish Cancer Institute, addresses the issue of choosing a first-line chemotherapy regimen based on an adenocarcinoma histology.

west cancer institute stage swedish iv platinum lung nsclc histology double t adenocarcinoma jack west squamous cisplatin paclitaxel taxol docetaxel gemcitabine carboplatin gracecast cancergrace taxane taxotere swedish cancer institute alimta gemzar pemetrexed gcvl gcvllung

Histology-Specific Regimens - Adenocarcinoma

Play Episode Listen Later Apr 16, 2016 2:53

Dr. Jack West, Swedish Cancer Institute, addresses the issue of choosing a first-line chemotherapy regimen based on an adenocarcinoma histology.

west cancer institute stage swedish iv platinum lung nsclc histology double t adenocarcinoma jack west squamous cisplatin paclitaxel taxol docetaxel gemcitabine carboplatin gracecast cancergrace taxane taxotere swedish cancer institute alimta gemzar pemetrexed gcvl gcvllung

What is the Role of Bevacizumab in Stage IV NSCLC?

Play Episode Listen Later Apr 15, 2016 3:46

Dr. Jack West, Swedish Cancer Institute, discusses the anti-angiogenic agent bevacizumab (Avastin) and the trial evidence of its efficacy for non-squamous NSCLC.

west cancer institute stage swedish iv platinum bleeding lung stage iv metastatic nsclc histology double t avastin bevacizumab jack west paclitaxel taxol ecog carboplatin gracecast cancergrace swedish cancer institute alimta pemetrexed 4599 nonsquamous gcvl gcvllung

What is the Role of Bevacizumab in Stage IV NSCLC?

Play Episode Listen Later Apr 15, 2016 3:46

Dr. Jack West, Swedish Cancer Institute, discusses the anti-angiogenic agent bevacizumab (Avastin) and the trial evidence of its efficacy for non-squamous NSCLC.

west cancer institute stage swedish iv platinum bleeding lung stage iv metastatic nsclc histology double t avastin bevacizumab jack west paclitaxel taxol ecog carboplatin gracecast cancergrace swedish cancer institute alimta pemetrexed 4599 nonsquamous gcvl gcvllung

What is the Role of Bevacizumab in Stage IV NSCLC?

Play Episode Listen Later Apr 15, 2016 3:46

Dr. Jack West, Swedish Cancer Institute, discusses the anti-angiogenic agent bevacizumab (Avastin) and the trial evidence of its efficacy for non-squamous NSCLC.

west cancer institute stage swedish iv platinum bleeding lung stage iv metastatic nsclc histology double t avastin bevacizumab jack west paclitaxel taxol ecog carboplatin gracecast cancergrace swedish cancer institute alimta pemetrexed 4599 nonsquamous gcvl gcvllung

Timing of Second Generation ALK Inhibitors: First Line vs. Treatment after Acquired Resistance

Play Episode Listen Later Apr 13, 2016 2:20

Dr. Ross Camidge, University of Colorado, addresses the question of whether to use a second generation ALK inhibitor as first line therapy or only after acquired resistance to crizotinib.

university colorado therapy cancer generation trial treatments resistance timing lung acquired inhibitors sequential first line second generation inhibitor alk nsclc rearrangement ross camidge jalex gracecast cancergrace acquired resistance crizotinib alectinib camidge gcvl gcvllung

Timing of Second Generation ALK Inhibitors: First Line vs. Treatment after Acquired Resistance

Play Episode Listen Later Apr 13, 2016 2:20

Dr. Ross Camidge, University of Colorado, addresses the question of whether to use a second generation ALK inhibitor as first line therapy or only after acquired resistance to crizotinib.

university colorado therapy cancer generation trial treatments resistance timing lung acquired inhibitors sequential first line second generation inhibitor alk nsclc rearrangement ross camidge jalex gracecast cancergrace acquired resistance crizotinib alectinib camidge gcvl gcvllung

Timing of Second Generation ALK Inhibitors: First Line vs. Treatment after Acquired Resistance

Play Episode Listen Later Apr 13, 2016 2:20

Dr. Ross Camidge, University of Colorado, addresses the question of whether to use a second generation ALK inhibitor as first line therapy or only after acquired resistance to crizotinib.

university colorado therapy cancer generation trial treatments resistance timing lung acquired inhibitors sequential first line second generation inhibitor alk nsclc rearrangement ross camidge jalex gracecast cancergrace acquired resistance crizotinib alectinib camidge gcvl gcvllung

CNS Disease in ALK-Positive NSCLC: Monitoring and Systemic vs. Radiation Therapy

Play Episode Listen Later Apr 12, 2016 2:30

Dr. Ross Camidge, University of Colorado, discusses management of CNS progression for ALK-positive NSCLC including monitoring frequency and preferences between systemic and radiation therapy.

university colorado brain positive therapy cancer generation disease monitoring progression mri systemic radiation lung cns srs inhibitor alk radiation therapy nsclc stereotactic radiosurgery rearrangement ross camidge gracecast cancergrace crizotinib camidge gcvl gcvllung

CNS Disease in ALK-Positive NSCLC: Monitoring and Systemic vs. Radiation Therapy

Play Episode Listen Later Apr 12, 2016 2:30

Dr. Ross Camidge, University of Colorado, discusses management of CNS progression for ALK-positive NSCLC including monitoring frequency and preferences between systemic and radiation therapy.

university colorado brain positive therapy cancer generation disease monitoring progression mri systemic radiation lung cns srs inhibitor alk radiation therapy nsclc stereotactic radiosurgery rearrangement ross camidge gracecast cancergrace crizotinib camidge gcvl gcvllung

CNS Disease in ALK-Positive NSCLC: Monitoring and Systemic vs. Radiation Therapy

Play Episode Listen Later Apr 12, 2016 2:30

Dr. Ross Camidge, University of Colorado, discusses management of CNS progression for ALK-positive NSCLC including monitoring frequency and preferences between systemic and radiation therapy.

university colorado brain positive therapy cancer generation disease monitoring progression mri systemic radiation lung cns srs inhibitor alk radiation therapy nsclc stereotactic radiosurgery rearrangement ross camidge gracecast cancergrace crizotinib camidge gcvl gcvllung

Crizotinib for First Line Treatment of ALK or ROS1 Rearrangements

Play Episode Listen Later Apr 10, 2016 0:56

Dr. Ross Camidge, University of Colorado, explains the preference for crizotinib rather than platinum doublet chemotherapy as first line treatment for patients with ALK or ROS1 rearrangements.

university colorado therapy cancer platinum targeted lung chemotherapy inhibitor alk nsclc double t first line treatment ros1 rearrangement ross camidge gracecast cancergrace crizotinib camidge gcvl gcvllung

Crizotinib for First Line Treatment of ALK or ROS1 Rearrangements

Play Episode Listen Later Apr 10, 2016 0:56

Dr. Ross Camidge, University of Colorado, explains the preference for crizotinib rather than platinum doublet chemotherapy as first line treatment for patients with ALK or ROS1 rearrangements.

university colorado therapy cancer platinum targeted lung chemotherapy inhibitor alk nsclc double t first line treatment ros1 rearrangement ross camidge gracecast cancergrace crizotinib camidge gcvl gcvllung

Crizotinib for First Line Treatment of ALK or ROS1 Rearrangements

Play Episode Listen Later Apr 10, 2016 0:56

Dr. Ross Camidge, University of Colorado, explains the preference for crizotinib rather than platinum doublet chemotherapy as first line treatment for patients with ALK or ROS1 rearrangements.

university colorado therapy cancer platinum targeted lung chemotherapy inhibitor alk nsclc double t first line treatment ros1 rearrangement ross camidge gracecast cancergrace crizotinib camidge gcvl gcvllung

ROS-1 Rearrangements: What Are They?

Play Episode Listen Later Apr 9, 2016 1:53

Dr. Ross Camidge, University of Colorado, describes ROS-1 rearrangements and compares them to ALK rearrangements in frequency of occurrence and response to treatment.

university colorado brain therapy cancer survival progression targeted lung inhibitor alk nsclc metastases ros1 rearrangement ross camidge gracecast cancergrace crizotinib camidge gcvl gcvllung

ROS-1 Rearrangements: What Are They?

Play Episode Listen Later Apr 9, 2016 1:53

Dr. Ross Camidge, University of Colorado, describes ROS-1 rearrangements and compares them to ALK rearrangements in frequency of occurrence and response to treatment.

university colorado brain therapy cancer survival progression targeted lung inhibitor alk nsclc metastases ros1 rearrangement ross camidge gracecast cancergrace crizotinib camidge gcvl gcvllung

ROS-1 Rearrangements: What Are They?

Play Episode Listen Later Apr 9, 2016 1:53

Dr. Ross Camidge, University of Colorado, describes ROS-1 rearrangements and compares them to ALK rearrangements in frequency of occurrence and response to treatment.

university colorado brain therapy cancer survival progression targeted lung inhibitor alk nsclc metastases ros1 rearrangement ross camidge gracecast cancergrace crizotinib camidge gcvl gcvllung

ALK Rearrangements: What Are They, and Who Has Them?

Play Episode Listen Later Apr 8, 2016 1:47

Dr. Ross Camidge, University of Colorado, describes ALK rearrangements and the characteristics of patients who most often have them.

university history colorado therapy cancer smoking targeted lung inhibitor alk nsclc adenocarcinoma rearrangement ross camidge gracecast cancergrace camidge gcvl gcvllung

ALK Rearrangements: What Are They, and Who Has Them?

Play Episode Listen Later Apr 8, 2016 1:47

Dr. Ross Camidge, University of Colorado, describes ALK rearrangements and the characteristics of patients who most often have them.

university history colorado therapy cancer smoking targeted lung inhibitor alk nsclc adenocarcinoma rearrangement ross camidge gracecast cancergrace camidge gcvl gcvllung

ALK Rearrangements: What Are They, and Who Has Them?

Play Episode Listen Later Apr 8, 2016 1:47

Dr. Ross Camidge, University of Colorado, describes ALK rearrangements and the characteristics of patients who most often have them.

university history colorado therapy cancer smoking targeted lung inhibitor alk nsclc adenocarcinoma rearrangement ross camidge gracecast cancergrace camidge gcvl gcvllung

Multiplex Testing for Rare Mutations: What Are the Potential Benefits?

Play Episode Listen Later Apr 7, 2016 2:56

Dr. Ross Camidge, University of Colorado, discusses the potential benefits as well as the disadvantages of multiplex mutation testing.

university colorado therapy cancer generation testing rare driver passenger targeted lung mutation ret sequencing sequential egfr multiplex alk nsclc potential benefits braf ros1 ross camidge gracecast cancergrace camidge gcvl gcvllung

Multiplex Testing for Rare Mutations: What Are the Potential Benefits?

Play Episode Listen Later Apr 7, 2016 2:56

Dr. Ross Camidge, University of Colorado, discusses the potential benefits as well as the disadvantages of multiplex mutation testing.

university colorado therapy cancer generation testing rare driver passenger targeted lung mutation ret sequencing sequential egfr multiplex alk nsclc potential benefits braf ros1 ross camidge gracecast cancergrace camidge gcvl gcvllung

Multiplex Testing for Rare Mutations: What Are the Potential Benefits?

Play Episode Listen Later Apr 7, 2016 2:56

Dr. Ross Camidge, University of Colorado, discusses the potential benefits as well as the disadvantages of multiplex mutation testing.

university colorado therapy cancer generation testing rare driver passenger targeted lung mutation ret sequencing sequential egfr multiplex alk nsclc potential benefits braf ros1 ross camidge gracecast cancergrace camidge gcvl gcvllung

The Role of Targeted Therapy Post-Resection

Play Episode Listen Later Apr 6, 2016 4:36

Dr. Heather Wakelee, Stanford University Medical Center, evaluates the lack of evidence for the use of targeted therapies after surgery, and describes ongoing trials attempting to resolve that issue.

university therapy cancer stage medical stanford surgery alchemists targeted lung radiant egfr alk nsclc targeted therapy adjuvant stanford university medical center resection wakelee gracecast cancergrace crizotinib erlotinib gcvl gcvllung

The Role of Targeted Therapy Post-Resection

Play Episode Listen Later Apr 6, 2016 4:36

Dr. Heather Wakelee, Stanford University Medical Center, evaluates the lack of evidence for the use of targeted therapies after surgery, and describes ongoing trials attempting to resolve that issue.

university therapy cancer stage medical stanford surgery alchemists targeted lung radiant egfr alk nsclc targeted therapy adjuvant stanford university medical center resection wakelee gracecast cancergrace crizotinib erlotinib gcvl gcvllung

The Role of Targeted Therapy Post-Resection